A Pilot Study of BTX-A51 in Patients With Metastatic and/or Recurrent Liposarcomas Characterized by MDM2 Amplifications
Latest Information Update: 06 May 2025
At a glance
- Drugs BTX A51 (Primary)
- Indications Liposarcoma
- Focus Adverse reactions
Most Recent Events
- 28 Apr 2025 According to Edgewood Oncology media release, new preclinical efficacy data supporting this trial, from an Investigator-Sponsored preclinical Study of BTX-A51 in liposarcoma models, has been presented at the American Association of Cancer Research (AACR) Annual Meeting taking place April 25-30, 2025, in Chicago. These data further support the ongoing clinical advancement of BTX-A51 in this investigator-sponsored Phase 1 pilot study.
- 30 Aug 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Nov 2024 to 1 Sep 2024.
- 30 Aug 2024 Status changed from not yet recruiting to recruiting.